Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Myeloproliferative/Myelodysplastic Neoplasms Presenting All Diagnostic Criteria of Chronic Myelomonocytic Leukemia but with Absolute Peripheral Blood Monocytosis 0.5-1× 10 9 /L Should be Classified As CMML

Sandra Castaño-Díez, Monica Lopez-Guerra, PhD, Daniel Esteban, Francesca Guijarro, MD, Alex Bataller Torralba, MD, Paola Charry, MD, Carlos Castillo, MD, Carlos Jiménez-Vicente, MD, Colomer Dolors, María Rozman, MD, Jordi Esteve, Marina Diaz-Beyá, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-142819

Published: 2020

Journal Articles

Emergence of NPM1 Wild-Type Myeloid Neoplasms after Chemotherapy for Acute Leukemia with NPM1 Mutation: Proposed Mechanisms of Clonal Evolution

Sandra Castaño-Díez, Monica Lopez-Guerra, PhD, Francesca Guijarro, MD, Alex Bataller Torralba, MD, Daniel Esteban, Carlos Castillo, MD, Carlos Jiménez-Vicente, MD, Paola Charry, MD, Colomer Dolors, María Rozman, MD, Jordi Esteve, Marina Diaz-Beyá, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-142740

Published: 2020

Journal Articles

Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140670

Published: 2020

Journal Articles

Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia

Neus Giménez Carabaza, B.Pharm, Rosich Laia, PhD, Schulz Ralph, MS, Higashi Morihiro, MD, Marta Aymerich, Neus Villamor, PhD, Julio Delgado, MD, Manel Juan, MD, Monica Lopez-Guerra, PhD, Elias Campo, Martina Seiffert, PhD, Dolors Colomer, PhD

Blood (2018) 132 (Supplement 1): 2650.

https://doi.org/10.1182/blood-2018-99-115999

Published: 2018

Journal Articles

Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations

Juan Gonzalo Correa, MD, Alberto Alvarez-Larrán, MD PhD, Monica Lopez-Guerra, PhD, Juan Carlos Hernandez Boluda, MD PhD, Mar Tormo, MD PhD, María Rozman, MD PhD, Daniel Martínez, MD, Dolors Colomer, PhD, Jordi Esteve, MD PhD, Francisco Cervantes, MD PhD

Blood (2018) 132 (Supplement 1): 4299.

https://doi.org/10.1182/blood-2018-99-115888

Published: 2018

Journal Articles

Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)

Blood (2018) 132 (Supplement 1): 1385.

https://doi.org/10.1182/blood-2018-99-110895

Published: 2018

Journal Articles

Notch1 Signaling in NOTCH1 -Mutated Mantle Cell Lymphoma Depends on DLL4 and Is a Potential Target for Specific Antibody Therapy

Elisabeth Höring, MD, Berta Colom Sanmarti, Silvia Xargay-Torrent, PhD, Walter E Aulitzky, MD, Heiko van der Kuip, PhD, Elias Campo, Mónica López-Guerra, PhD, Dolors Colomer, PhD

Blood (2016) 128 (22): 1846.

https://doi.org/10.1182/blood.V128.22.1846.1846

Published: 2016

NARROW

Myeloproliferative/Myelodysplastic Neoplasms Presenting All Diagnostic Criteria of Chronic Myelomonocytic Leukemia but with Absolute Peripheral Blood Monocytosis 0.5-1× 10 9 /L Should be Classified As CMML

Emergence of NPM1 Wild-Type Myeloid Neoplasms after Chemotherapy for Acute Leukemia with NPM1 Mutation: Proposed Mechanisms of Clonal Evolution

Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)

Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia

Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations

Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)

Notch1 Signaling in NOTCH1 -Mutated Mantle Cell Lymphoma Depends on DLL4 and Is a Potential Target for Specific Antibody Therapy

Email alerts

ASH Publications

American Society of Hematology

Myeloproliferative/Myelodysplastic Neoplasms Presenting All Diagnostic Criteria of Chronic Myelomonocytic Leukemia but with Absolute Peripheral Blood Monocytosis 0.5-1× 10 9 /L Should be Classified As CMML

Emergence of NPM1 Wild-Type Myeloid Neoplasms after Chemotherapy for Acute Leukemia with NPM1 Mutation: Proposed Mechanisms of Clonal Evolution

Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)

Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia

Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations

Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)

Notch1 Signaling in NOTCH1 -Mutated Mantle Cell Lymphoma Depends on DLL4 and Is a Potential Target for Specific Antibody Therapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only